文献速递消化系统肿瘤

凡德他尼联合吉西他滨对比安慰剂联合吉西他滨治疗局部晚期或转移性胰腺癌(ViP):一项前瞻性、随机、双盲、多中心2期试验

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
PubMed 文献 · Lancet Oncol · 2017-03-02

ViP试验为2期双盲安慰剂对照多中心随机试验,142例初治局部晚期或转移性胰腺癌患者随机接受凡德他尼联合吉西他滨或安慰剂联合吉西他滨,中位总生存期分别为8.83个月和8.95个月(HR 1.21,P=0.303),联合凡德他尼未改善总生存。

要点

  • 凡德他尼联合吉西他滨对比安慰剂联合吉西他滨,中位总生存期8.83个月 vs 8.95个月(HR 1.21,P=0.303),无显著差异。
  • 3-4级不良事件最常见中性粒细胞减少:凡德他尼组35/72(49%)vs 安慰剂组22/70(31%)。
  • 研究期间未发生治疗相关死亡。

核心结论

  • 在吉西他滨单药基础上加用凡德他尼未改善晚期胰腺癌患者的总生存期。
  • 酪氨酸激酶抑制剂在胰腺癌治疗中可能仍有潜力,但进一步开发需要识别生物标志物以特异性地筛选出敏感的癌症亚型。

研究设计与样本

  • ViP试验为2期双盲、多中心、随机、安慰剂对照试验,纳入既往未经治疗的成人(年龄≥18岁)局部晚期或转移性胰腺癌患者。
  • 患者按1:1随机分配至凡德他尼联合吉西他滨组(凡德他尼组)或安慰剂联合吉西他滨组(安慰剂组),随机化时按疾病分期和ECOG体能状态分层。
  • 所有患者接受吉西他滨1000 mg/m2,30分钟静脉输注,每周一次,连续7周后休息1周,之后为3周治疗加1周休息的周期,直至疾病进展,同时每日一次口服凡德他尼300 mg或匹配安慰剂。
  • 2011年10月24日至2013年10月7日筛查并入组,筛查381例患者,142例合格患者被随机分配(凡德他尼组72例,安慰剂组70例)。
  • 主要结局指标为意向治疗人群的总生存期(定义为从随机化至任何原因死亡或删失日期的时间差)。

主要发现

  • 数据截止于2015年7月15日,中位随访24.9个月(IQR 24.3至不可达)时,131例患者死亡:凡德他尼组72例中70例(97%),安慰剂组70例中61例(87%)。
  • 凡德他尼组中位总生存期为8.83个月(95% CI 7.11-11.58),安慰剂组为8.95个月(6.55-11.74)(风险比1.21,80.8% CI 0.95-1.53;log rank χ21df 1.1,p=0.303)。
  • 最常见的3-4级不良事件为中性粒细胞减少(凡德他尼组72例中35例[49%] vs 安慰剂组70例中22例[31%])、血小板减少(20例[28%] vs 16例[23%])、高血压(9例[13%] vs 11例[16%])、白细胞减少(12例[17%] vs 13例[19%])和乏力(17例[24%] vs 15例[21%])。
  • 研究期间未发生治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer. METHODS: The Vandetanib in Pancreatic Cancer (ViP) trial was a phase 2 double-blind, multicentre, randomised placebo-controlled trial in previously untreated adult patients (aged ≥18 years) diagnosed with locally advanced or metastatic carcinoma of the pancreas confirmed by cytology or histology. Patients had to have an Eastern Cooperative Oncology Group (ECOG) score of 0-2 and a documented life expectancy of at least 3 months. Patients were randomly assigned 1:1 to receive vandetanib plus gemcitabine (vandetanib group) or placebo plus gemcitabine (placebo group) according to pre-generated sequences produced on the principle of randomly permuted blocks with variable block sizes of two and four. Patients were stratified at randomisation by disease stage and ECOG performance status. All patients received gemcitabine 1000 mg/m2 as a 30-min intravenous infusion, weekly, for 7 weeks followed by a 1-week break, followed by a cycle of 3 weeks of treatment with a 1-week break, until disease progression, and either oral vandetanib 300 mg per day once daily or matching placebo. Patients and investigators were masked to treatment assignment. The primary outcome measure was overall survival (defined as the difference in time between randomisation and death from any cause or the censor date) in the intention-to-treat population. This trial has been completed and the final results are reported. The study is registered at EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. FINDINGS: Patients were screened and enrolled between Oct 24, 2011, and Oct 7, 2013. Of 381 patients screened, 142 eligible patients were randomly assigned to treatment (72 to the vandetanib group and 70 to the placebo group). At database lock on July 15, 2015, at a median follow-up of 24·9 months (IQR 24·3 to not attainable), 131 patients had died: 70 (97%) of 72 in the vandetanib group and 61 (87%) of 70 in the placebo group. The median overall survival was 8·83 months (95% CI 7·11-11·58) in the vandetanib group and 8·95 months (6·55-11·74) in the placebo group (hazard ratio 1·21, 80·8% CI 0·95-1·53; log rank χ21df 1·1, p=0·303). The most common grade 3-4 adverse events were neutropenia (35 [49%] of 72 patients in the vandetanib group vs 22 [31%] of 70 in the placebo group), thrombocytopenia (20 [28%] vs 16 [23%]), hypertension (nine [13%] vs 11 [16%]), leucopenia (12 [17%] vs 13 [19%]), and fatigue (17 [24%] vs 15 [21%]). No treatment-related deaths occurred during the study. INTERPRETATION: The addition of vandetanib to gemcitabine monotherapy did not improve overall survival in advanced pancreatic cancer. Tyrosine kinase inhibitors might still have potential in the treatment of pancreatic cancer but further development requires the identification of biomarkers to specifically identify responsive cancer subtypes. FUNDING: Cancer Research UK and AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Middleton G, Palmer DH, Greenhalf W, et al. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncol. 2017. PMID: 28259610. doi:10.1016/S1470-2045(17)30084-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。